Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 Indication name: Post-traumatic stress disorder (PTSD)

Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Post-traumatic stress disorder (PTSD) is a complex mental disorder with psychological and emotional components, caused by exposure to single or repeated extreme traumatic events found in war, terrorist attacks, natural or man-caused disasters, and by violent personal assaults and accidents.

Epidemiology-

According to Thelansis, The lifetime prevalence of PTSD ranges from 5.7 to 8.8 percent in national samples of the general adult population in the United States, with one-year prevalence rates of 4.2 to 5.1 percent.

Competitive landscape of Post-traumatic stress disorder (PTSD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Post-traumatic stress disorder (PTSD) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Post-traumatic stress disorder (PTSD) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 NYX-783 Aptinyx Phase 2
2 Nabiximols GW Pharmaceuticals Ltd. Phase 3
3 NBTX-001 Xenon Inhaler Nobilis Therapeutics Inc. Phase 3
4 BNC210 Bionomics Limited Phase 2
5 Brexpiprazole (OPC-34712) Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3
6 CBD Cannabis Tilray Phase 2
7 orvepitant GlaxoSmithKline Phase 2
8 BX-1 Bionorica SE Phase 2
9 Ganaxolone Marinus Pharmaceuticals Phase 2
10 Lu AG06466 H. Lundbeck A/S Phase 1
11 MDMA MAPS Europe B.V. Phase 2
12 Nepicastat Acorda Therapeutics Phase 2
13 TNX-102 SL 5.6 mg Tonix Pharmaceuticals, Inc. Phase 3

Respiratory syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Respiratory syncytial virus (RSV) is a filamentous enveloped, negative-sense, single-stranded RNA virus that belongs to the Orthopneumovirus genus of the Pneumoviridae family in the order Mononegavirales. This family also contains human metapneumovirus (hMPV), which belongs to the Metapneumovirus genus and, like RSV, is a major pathogen in children. The symptoms of RSV and hMPV infection are indistinguishable, and both are generally transmitted through close contact.

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, and surveys estimated in the United States, nearly all children become infected with RSV by age 2, with 95,000 to 135,000 of them hospitalized each year. Approximately 0.5% to 2.0% of all children are hospitalized with lower respiratory tract disease, of which 50% to 90% face bronchiolitis and 5% to 40% encounter pneumonia. Globally, RSV affects an estimated 64 million people and causes 160,000 deaths each year.

Competitive landscape of Respiratory syncytial virus (RSV) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Respiratory syncytial virus (RSV) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Respiratory syncytial virus (RSV) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

 

Read more: Respiratory syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 GSK3844766A GlaxoSmithKline Phase 2
2 ALN-RSV01 Alnylam Pharmaceuticals Phase 2
3 EDP-938 Enanta Pharmaceuticals Phase 2
4 Presatovir Gilead Sciences Phase 2
5 PC786 Pulmocide Ltd Phase 2
6 MEDI8897 MedImmune LLC Phase 3
7 ALS-008176 Alios Biopharma Inc. Phase 1
8 MV-012-968 Meissa Vaccines, Inc. Phase 1
9 CodaVax-RSV Codagenix, Inc Phase 1
10 MVA-mBN294B Bavarian Nordic Phase 2
 

Ornithine Transcarbamylase (OTC) Deficiency – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Ornithine Transcarbamylase (OTC) Deficiency

Ornithine Transcarbamylase (OTC) Deficiency – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Ornithine Transcarbamylase (OTC) Deficiency - OTC is a mitochondrial matrix enzyme and catalyzes the condensation of carbamoylphosphate and ornithine to form citrulline. The gene encoding OTC is at Xp21.1. Patients with OTC deficiency, like other inborn errors of metabolism, represent a range of disease severity correlating with the degree of residual enzymatic function. Ornithine transcarbamylase deficiency (OTCD), an X-linked disorder, is the most common urea cycle disorder (UCD).

Epidemiology-
According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the estimated incidence rate is 1/17 000 in the USA.

Competitive landscape of Ornithine Transcarbamylase (OTC) Deficiency includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Ornithine Transcarbamylase (OTC) Deficiency8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Ornithine Transcarbamylase (OTC) Deficiency market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Ornithine Transcarbamylase (OTC) Deficiency – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 ARCT-810 Arcturus Therapeutics, Inc. Phase 2
2 scAAV8OTC Ultragenyx Pharmaceutical Inc Phase 2
3 Human Heterologous Liver Cells Cytonet GmbH & Co. KG Phase 2
4 KB195 Kaleido Biosciences Phase 2

Epidermolysis Bullosa (EB) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Epidermolysis Bullosa (EB)

Epidermolysis bullosa (EB) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Epidermolysis bullosa (EB) is a group of inherited diseases that are characterised by blistering lesions on the skin and mucous membranes.

Classification-there are four major types of EB based on different sites of blister formation within the skin structure:

Epidermolysis bullosa simplex (EBS) - Epidermis or uppermost layer of skin cells (keratinocytes), Junctional epidermolysis bullosa (JEB)- Lamina lucida within the basement membrane zone, Dystrophic epidermolysis bullosa (DEB)- Lamina densa and upper dermis, Kindler syndrome- Mixed pattern or multiple levels within and beneath the basement membrane zone.

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the prevalence rate of Epidermolysis bullosa (EB) is between a range of 10.8 to 11.4 per one million live births with an incidence of 1 in every 51,000 live births.

Competitive landscape of Epidermolysis bullosa (EB) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Epidermolysis bullosa (EB) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Epidermolysis bullosa (EB) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Epidermolysis Bullosa (EB) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No Asset Company Partner Phase
1 FCX-007 Castle Creek Pharmaceuticals LLC Intrexon; Fibrocell Science III
2 RGN-137 G-treeBNT Co., Ltd Lee's Pharmaceutical; RegeneRx II
3 EB-101 Abeona Therapeutics, Inc. N/A I/II
4 KB103 Krystal Biotech, Inc. N/A I/II
5 PTR-01 BridgeBio Inc. N/A I/II
6 QR-313 Wings Therapeutics N/A I/II
7 Topical 31510 Berg Pharma, LLC N/A I
8 S-005151 Shionogi & Co. Ltd. StemRIM Investigator Initiated
9 Serlopitant Menlo Therapeutics, Inc. VPD Investigator Initiated
10 AC-201 TWi Pharmaceuticals, Inc. N/A Development Outside U.S.
11 allo-APZ2 TICEBA GmbH N/A Development Outside U.S.
12 CCP-020 Castle Creek Pharmaceuticals LLC TWi Pharmaceuticals Development Outside U.S.
13 CL-2020 Mitsubishi Tanabe Pharma Corporation N/A Development Outside U.S.
14 Episalvan Amryt Pharma plc N/A Development Outside U.S.
15 INM-755 InMed Pharmaceuticals Ltd. N/A Development Outside U.S.
16 Prochymal Mesoblast Limited JCR Pharmaceuticals; Mallinckrodt; Smith & Nephew Development Outside U.S.
17 TXA127 Constant Therapeutics, LLC Unigene Laboratories Preclinical

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Cushing’s Syndrome (CS)

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

 

Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cushing’s syndrome can be caused by overuse of cortisol medication, as seen in the treatment of chronic asthma or rheumatoid arthritis (iatrogenic Cushing’s syndrome), excess production of cortisol from a tumor in the adrenal gland or elsewhere in the body (ectopic Cushing’s syndrome) or a tumor of the pituitary gland secreting adrenocorticotropic hormone (ACTH) which stimulates the over-production of cortisol from the adrenal gland (Cushing’s disease).

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, pituitary ACTH-dependent Cushing's causes 68% to 72% of Cushing's syndrome. The reported incidence was 1.53 to 2.43 per million per year in European population-based studies and 6.3 to 7.3 per million person-years in the United States

Competitive landscape of Cushing’s Syndrome (CS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Cushing’s Syndrome (CS) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Cushing’s Syndrome (CS) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

 

Read more: Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No Asset Company Partner Phase
1 Korlym Corcept Therapeutics Inc. N/A Approved
2 Signifor Recordati SpA Novartis Approved
3 Ketoconazole HRA Pharma N/A Approved in Europe
4 Cytadren Novartis AG N/A Withdrawn from Market
5 Osilodrostat Recordati SpA Novartis NDA
6 Recorlev Strongbridge Biopharma plc N/A III
7 Relacorilant Corcept Therapeutics Inc. N/A III
8 Mifedren HRA Pharma N/A II/III
9 Nevanimibe Millendo Therapeutics, Inc. N/A II
10 Lysodren HRA Pharma N/A Investigator Initiated
11 Seliciclib Cyclacel Pharmaceuticals, Inc. ManRos Therapeutics Investigator Initiated
12 COR-005 Strongbridge Biopharma plc Evotec Development Outside U.S.
13 HTL0030310 Sosei Co., Ltd N/A Development Outside U.S.
14 ACTH Antagonist (Crinetics) Crinetics Pharmaceuticals, Inc. N/A Preclinical
15 Anti-ACTH XOMA Corporation N/A Preclinical
16 AP102 Amryt Pharma plc N/A Preclinical
17 BIM23B065 Ipsen SA N/A Preclinical
18 Steroidogenic factor-1 (SF-1) Antagonists Orphagen Pharmaceuticals N/A Preclinical

Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030

Indication name: Charcot-Marie-Tooth (CMT)

Charcot-Marie-Tooth (CMT) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Charcot-Marie-Tooth disease (CMT) is one of a group of disorders that cause damage to the peripheral nerves—the nerves that transmit information and signals from the brain and spinal cord to and from the rest of the body, as well as sensory information such as touch back to the spinal cord and brain. CMT is caused by mutations in genes that support or produce proteins involved in the structure and function of either the peripheral nerve axon or the myelin sheath. More than 40 genes have been identified in CMT, with each gene linked to one or more types of the disease. In addition, multiple genes can be linked to one type of CMT. More than half of all cases of CMT are caused by a duplication of the PMP22 gene on chromosome 17.

Classification-

There are different types of CMT disease such as; CMT1, CMT2, CMT3 (Dejerine-Sottas disease), CMT4, CMTX1 (also called CMT X, Type 1)

Epidemiology-

CMT is one of the most common inherited neurological disorders, affecting an estimated 148,000 individuals in the United States and > 3.2 million people worldwide.

Competitive landscape of Acromegaly includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Charcot-Marie-Tooth (CMT) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Charcot-Marie-Tooth (CMT) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030

S. No Asset Company Partner Phase
1 PXT3003 Pharnext SA Tasly Pharmaceutical Group III
2 NT-3 Gene Therapy Nationwide Children’s Hospital Sarepta Therapeutics I/II
3 IFB-088 InFlectis BioScience N/A I
4 Engensis Helixmith Co., Ltd. Northland Status to confirm
5 CMT4J Disease Therapy Neurogene Inc. N/A Preclinical
6 Ricolinostat Bristol-Myers Squibb Company Regenacy Preclinical 
 

Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Acromegaly

Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. Acromegaly may also cause thickening of the soft tissues of the body, including the heart, lips, and tongue. When the disease affects children prior to the end of puberty, excess growth hormone can lead to accelerated growth and tall stature, known as gigantism. Acromegaly may be caused by the ineffective control of growth hormone-secreting cells by the hypothalamus (a gland in the brain that regulates hormone secretions).

In rare cases, non-pituitary tumors in the pancreas, lungs or adrenal glands may cause acromegaly. In some cases, acromegaly may occur as part of certain genetic syndromes including multiple endocrine neoplasia type 1, familial isolated pituitary adenoma, the Carney complex and McCune-Albright syndrome. X-linked acrogigantism causes gigantism and is due to microduplications of segments of the X chromosome.

Epidemiology-
About 3 to 14 of every 100,000 people have been diagnosed as having acromegaly.

Competitive landscape of Acromegaly includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Acromegaly 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Acromegaly market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No Asset Company Stage
1 Sandostatin Novartis AG Approved (Generic Competition)
2 Sandostatin LAR Novartis AG Approved
3 Signifor Recordati SpA Approved
4 Somatuline Autogel Ipsen SA Approved
5 Somavert Nektar Therapeutics Approved
6 CAM2029 Novartis AG III
7 Mycapssa Chiasma, Inc III
8 ATL1103 Antisense Therapeutics, Ltd. II
9 COR-005 Strongbridge Biopharma plc II
10 CRN00808 Crinetics Pharmaceuticals, Inc. II
11 IONIS-GHR-LRx Ionis Pharmaceuticals, Inc. II
12 DP1038 Dauntless Pharmaceuticals, Inc. I
13 Glide Octreotide Enesi Pharma Limited I
14 ONO-5788 Ono Pharmaceutical Company, Ltd. I
15 Q-Octreotide Midatech Pharma PLC I
16 ITF-2984 Italfarmaco S.p.A. Development Outside U.S.
17 AP102 Amryt Pharma plc Preclinical
18 AQST-305 Aquestive Therapeutics, Inc Preclinical